CST, 3180T, Fatty Acid Synthase (C20G5) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying FASN. Validated for WB,IP,IHC,IF,F. Available in 2 sizes. Highly specific and rigorously validated in-house, Fatty Acid Synthase (C20G5) Rabbit Monoclonal Antibody (CST #3180) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Immunohistochemistry (Paraffin): 1:50 - 1:200 Immunofluorescence (Immunocytochemistry): 1:50 Flow Cytometry (Fixed/Permeabilized): 1:50 - 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation, Immunohistochemistry (Paraffin), Immunofluorescence (Immunocytochemistry), Flow Cytometry (Fixed/Permeabilized) Specificity / Sensitivity Fatty Acid Synthase (C20G5) Rabbit Monoclonal Antibody detects endogenous levels of total fatty acid synthase protein. Reactivity by immunofluorescence is human only. Species Reactivity: Human, Mouse, Rat Source / Purification Fatty Acid Synthase (C20G5) Rabbit mAb is produced by immunizing rabbits with a synthetic peptide around Gly46 corresponding to the sequence of human fatty acid synthase. Background Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1). According to the research literature, increased expression of FASN has emerged as a phenotype common to most human carcinomas. For example, in breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Research studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7). Alternate Names [Acyl-carrier-protein] S-acetyltransferase; [Acyl-carrier-protein] S-malonyltransferase; 3-hydroxyacyl-[acyl-carrier-protein] dehydratase; 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-oxoacyl-[acyl-carrier-protein] synthase; Acyl-[acyl-carrier-protein] hydrolase; Enoyl-[acyl-carrier-protein] reductase; FAS; FASN; Fatty acid synthase; MGC14367; MGC15706; OA-519; Oleoyl-[acyl-carrier-protein] hydrolase; SDR27X1; short chain dehydrogenase/reductase family 27X, member 1; Type I fatty acid synthase Specification REACTIVITY: H M R SENSITIVITY: Endogenous MW (kDa): 273 Source/Isotype: Rabbit IgG